Dashenlin Pharmaceutical's AGM approves 2024 profit distribution plan

Dashenlin Pharmaceutical Group Co., Ltd. (SSE:603233) announced the resolutions passed at its 2024 Annual General Meeting held on May 20, 2025. Key approvals included the 2024 annual report and summary, the 2024 profit distribution plan, and the re-appointment of Tianjian CPA as the company's auditor for 2025. Shareholders holding 881,424,470 shares, representing 77.8557% of the company's total voting shares, attended the meeting. The resolution for the 2024 profit distribution plan was approved with 99.9882% of the votes in favor. Additionally, proposals related to affiliated transactions, credit facility applications, and remuneration for directors, supervisors, and senior management were also approved. All resolutions were passed via a combination of on-site and online voting.